Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort

Nathan Vidal^{1

2}, Paul Roux^{1

2}, Mathieu Urbach^{1

2}, Cristobal Belmonte^{1

3}, Laurent Boyer^{1

4}, Delphine Capdevielle^{1

3

5}, Julie Clauss-Kobayashi^{1

6}, Thierry D'Amato^{1

7}, Romane Dassing^{1

6}, Caroline Dubertret^{1

8}, Julien Dubreucq^{1

9}, Guillaume Fond^{1

4}, Roxana-Mihaela Honciuc^{1

10}, Sylvain Leignier^{1

9}, Pierre-Michel Llorca^{1

10}, Jasmina Mallet^{1

8}, David Misdrahi^{1

11}, Baptiste Pignon^{1

12}, Romain Rey^{1

7}, Franck Schürhoff^{1

12}, Arnaud Tessier^{1

11}; FACE-SZ (FondaMental Academic Centers of Expertise—Schizophrenia) Group; Christine Passerieux^{1

2}, Eric Brunet-Gouet^{1

2}

Collaborators, Affiliations

Collaborators

FACE-SZ (FondaMental Academic Centers of Expertise—Schizophrenia) Group:
B Aouizerate, V Barteau, S Bensalem, F Berna, O Blanc, E Bourguignon, L Boyer, D CapdevielleI Chéreau, G Chesnoy-Servanin, T D'Amato, A Deloge, H Denizot, J M Dorey, C Dubertret, J Dubreucq, S Esselin, C Faget, C Fluttaz, G Fond, F Gabayet, O Godin, E Haffen, R M Honciuc, M Jarroir, D Lacelle, C Lançon, H Laouamri, M Leboyer, P M Llorca, J Mallet, E Metairie, D Misdrahi, C Passerieux, J Petrucci, P Peri, B Pignon, S Pires, C Portalier, R Rey, C Roman, F Schürhoff, K Souryis, A Szöke, M Urbach, F Vaillant, A, Vehier, P Vidailhet, E Vilà, G Wahiche, H Yazbek, A Zinetti-Bertschy

Affiliations

¹ FondaMental Foundation, Créteil, France.
² Centre Hospitalier de Versailles, Service universitaire de psychiatrie d'adultes et d'addictologie, Le Chesnay, Université Paris-Saclay, Université de Versailles Saint-Quentin-En-Yvelines, DisAP-DevPsy-CESP, Institut National de la Santé et de la Recherche Médicale (INSERM), Villejuif, France.
³ University Department of Adult Psychiatry, Hospital La Colombière, CHU Montpellier, Montpellier, France.
⁴ EA 3279: Department of Epidemiology and Health Economics, School of Medicine-La Timone Medical Campus, Marseille University Hospital, Aix-Marseille University, Marseille, France.
⁵ Institute of Functional Genomics, University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Montpellier, France.
⁶ Department of Psychiatry, University Hospitals of Strasbourg, University of Strasbourg, Institut National de la Santé et de la Recherche Médicale (INSERM), Strasbourg, France.
⁷ Le Vinatier Hospital, Schizophrenia Expert Centre, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), University Lyon 1, Lyon Neuroscience Research Center, PSYR2 Team, Lyon, France.
⁸ Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Psychiatry, Louis Mourier Hospital, Institut National de la Santé et de la Recherche Médicale (INSERM), Institute of Psychiatry and Neuroscience of Paris, University Paris Descartes, Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
⁹ Grenoble Alpes University, Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Grenoble Alpes, Grenoble Institute of Neurosciences, Grenoble, France.
¹⁰ CHU Clermont-Ferrand, Service of psychiatry B, University of Clermont Auvergne, Clermont-Ferrand, France.
¹¹ Department of Universitary and General Psychiatry, Charles Perrens Hospital, University of Bordeaux, Aquitaine Institute for Cognitive and Integrative Neuroscience (CNRS UMR 5287-INCIA, ECOPSY), Bordeaux, France.
¹² Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires "H. Mondor", DMU IMPACT, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de Recherche Médicale (IMRB), Translational Neuropsychiatry, University Paris-Est-Créteil (UPEC), Créteil, France.

PMID: 38933674
PMCID: PMC11200119
DOI: 10.3389/fphar.2024.1403093

Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort

Nathan Vidal et al. Front Pharmacol. 2024.

. 2024 Jun 12:15:1403093.

doi: 10.3389/fphar.2024.1403093. eCollection 2024.

Authors

Collaborators

FACE-SZ (FondaMental Academic Centers of Expertise—Schizophrenia) Group:
B Aouizerate, V Barteau, S Bensalem, F Berna, O Blanc, E Bourguignon, L Boyer, D CapdevielleI Chéreau, G Chesnoy-Servanin, T D'Amato, A Deloge, H Denizot, J M Dorey, C Dubertret, J Dubreucq, S Esselin, C Faget, C Fluttaz, G Fond, F Gabayet, O Godin, E Haffen, R M Honciuc, M Jarroir, D Lacelle, C Lançon, H Laouamri, M Leboyer, P M Llorca, J Mallet, E Metairie, D Misdrahi, C Passerieux, J Petrucci, P Peri, B Pignon, S Pires, C Portalier, R Rey, C Roman, F Schürhoff, K Souryis, A Szöke, M Urbach, F Vaillant, A, Vehier, P Vidailhet, E Vilà, G Wahiche, H Yazbek, A Zinetti-Bertschy

Affiliations

¹ FondaMental Foundation, Créteil, France.
² Centre Hospitalier de Versailles, Service universitaire de psychiatrie d'adultes et d'addictologie, Le Chesnay, Université Paris-Saclay, Université de Versailles Saint-Quentin-En-Yvelines, DisAP-DevPsy-CESP, Institut National de la Santé et de la Recherche Médicale (INSERM), Villejuif, France.
³ University Department of Adult Psychiatry, Hospital La Colombière, CHU Montpellier, Montpellier, France.
⁴ EA 3279: Department of Epidemiology and Health Economics, School of Medicine-La Timone Medical Campus, Marseille University Hospital, Aix-Marseille University, Marseille, France.
⁵ Institute of Functional Genomics, University of Montpellier, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Montpellier, France.
⁶ Department of Psychiatry, University Hospitals of Strasbourg, University of Strasbourg, Institut National de la Santé et de la Recherche Médicale (INSERM), Strasbourg, France.
⁷ Le Vinatier Hospital, Schizophrenia Expert Centre, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), University Lyon 1, Lyon Neuroscience Research Center, PSYR2 Team, Lyon, France.
⁸ Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Psychiatry, Louis Mourier Hospital, Institut National de la Santé et de la Recherche Médicale (INSERM), Institute of Psychiatry and Neuroscience of Paris, University Paris Descartes, Université Paris Diderot, Sorbonne Paris Cité, Faculté de Médecine, Paris, France.
⁹ Grenoble Alpes University, Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Grenoble Alpes, Grenoble Institute of Neurosciences, Grenoble, France.
¹⁰ CHU Clermont-Ferrand, Service of psychiatry B, University of Clermont Auvergne, Clermont-Ferrand, France.
¹¹ Department of Universitary and General Psychiatry, Charles Perrens Hospital, University of Bordeaux, Aquitaine Institute for Cognitive and Integrative Neuroscience (CNRS UMR 5287-INCIA, ECOPSY), Bordeaux, France.
¹² Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires "H. Mondor", DMU IMPACT, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de Recherche Médicale (IMRB), Translational Neuropsychiatry, University Paris-Est-Créteil (UPEC), Créteil, France.

PMID: 38933674
PMCID: PMC11200119
DOI: 10.3389/fphar.2024.1403093

Abstract

Aim: The anticholinergic properties of medications are associated with poorer cognitive performance in schizophrenia. Numerous scales have been developed to assess anticholinergic burden and yet, there is no consensus indicating which anticholinergic burden scale is more relevant for patients with schizophrenia. We aimed to identify valid scales for estimating the risk of iatrogenic cognitive impairment in schizophrenia.

Methods: We identified 27 scales in a literature review. The responses to neuropsychological tests of 839 individuals with schizophrenia or schizoaffective disorder in the FACE-SZ database were collected between 2010 and 2021. We estimated the association between objective global cognitive performance and the 27 scales, the number of psychotropic drugs, and chlorpromazine and lorazepam equivalents in bivariable regressions in a cross-sectional design. We then adjusted the bivariable models with covariates: the predictors significantly associated with cognitive performance in multiple linear regressions were considered to have good concurrent validity to assess cognitive performance.

Results: Eight scales, the number of psychotropic drugs, and drug equivalents were significantly associated with cognitive impairment. The number of psychotropic drugs, the most convenient predictor to compute, was associated with worse executive function (Standardized β = -0.12, p = .004) and reasoning (Standardized β = -0.08, p = .037).

Conclusion: Anticholinergic burden, the number of psychotropic drugs, and drug equivalents were weakly associated with cognition, thus suggesting that cognitive impairment in schizophrenia and schizoaffective disorder is explained by factors other than medication. The number of psychotropic drugs was the most parsimonious method to assess the risk of iatrogenic cognitive impairment.

Keywords: cholinergic antagonist; neuropsychological test; polypharmacy; psychotropic drug; schizophrenia.

Copyright © 2024 Vidal, Roux, Urbach, Belmonte, Boyer, Capdevielle, Clauss-Kobayashi, D’Amato, Dassing, Dubertret, Dubreucq, Fond, Honciuc, Leignier, Llorca, Mallet, Misdrahi, Pignon, Rey, Schürhoff, Tessier, the FACE-SZ (FondaMental Academic Centers of Expertise—Schizophrenia) Group, Passerieux and Brunet-Gouet.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

**FIGURE 1**
Results of the bivariable linear regression models of cognitive impairment with the 27 scales as the predictor. Significant (p < 0.05) associations are shown in red. The total anticholinergic burden score was computed by either summing the scores of each treatment (SUM) or by using the maximum score (MAX).

See this image and copyright information in PMC

References

1. Addington D., Addington J., Maticka-Tyndale E., Joyce J. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 6 (3), 201–208. 10.1016/0920-9964(92)90003-n - DOI - PubMed
1. Al Rihani S. B., Deodhar M., Darakjian L. I., Dow P., Smith M. K., Bikmetov R., et al. (2021). Quantifying anticholinergic burden and sedative load in older adults with polypharmacy: a systematic review of risk scales and models. Drugs Aging 38 (11), 977–994. 10.1007/s40266-021-00895-x - DOI - PMC - PubMed
1. Andreasen N. C., Pressler M., Nopoulos P., Miller D., Ho B. C. (2010). Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 67 (3), 255–262. 10.1016/j.biopsych.2009.08.040 - DOI - PMC - PubMed
1. Ang M. S., Abdul Rashid N. A., Lam M., Rapisarda A., Kraus M., Keefe R. S. E., et al. (2017). The impact of medication anticholinergic burden on cognitive performance in people with schizophrenia. J. Clin. Psychopharmacol. 37 (6), 651–656. 10.1097/JCP.0000000000000790 - DOI - PMC - PubMed
1. Baddeley A. D., Emslie H., Nimmo-Smith I. (2006). Doors and people: a test of visual and verbal recall and recognition. San Antonio, TX, USA: Harcourt Assessment.

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort

Collaborators

Affiliations

Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment in schizophrenia: results from the multicenter FACE-SZ cohort

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources